PARP1 and neoplasm: Jiao et al. further demonstrated that pharmacologic inhibition of PARP1 leads to upregulation of PD-L1 in tumor cells, suggesting an immunomodulatory axis involving ADP-ribosylation and immune escape mechanisms [6].